[go: up one dir, main page]

MX2016005394A - Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. - Google Patents

Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.

Info

Publication number
MX2016005394A
MX2016005394A MX2016005394A MX2016005394A MX2016005394A MX 2016005394 A MX2016005394 A MX 2016005394A MX 2016005394 A MX2016005394 A MX 2016005394A MX 2016005394 A MX2016005394 A MX 2016005394A MX 2016005394 A MX2016005394 A MX 2016005394A
Authority
MX
Mexico
Prior art keywords
ring
fused bicyclic
pyridyl derivatives
fgfr4 inhibitors
compound
Prior art date
Application number
MX2016005394A
Other languages
English (en)
Other versions
MX367723B (es
Inventor
Wang Can
Zhao Xianglin
Furet Pascal
Alec Fairhurst Robin
Liao Lv
Buschmann Nicole
Knöpfel Thomas
Leblanc Catherine
Mah Robert
Nimsgern Pierre
Ripoche Sebastien
Xiong Jing
Han Bo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016005394A publication Critical patent/MX2016005394A/es
Publication of MX367723B publication Critical patent/MX367723B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo; (ver Fórmula) Un método para fabricar dicho compuesto, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacologicamente activos y una composición farmacéutica que comprende dicho compuesto.
MX2016005394A 2013-10-25 2014-10-24 Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4. MX367723B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013086003 2013-10-25
CN2014088094 2014-10-03
PCT/IB2014/065585 WO2015059668A1 (en) 2013-10-25 2014-10-24 Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Publications (2)

Publication Number Publication Date
MX2016005394A true MX2016005394A (es) 2016-08-12
MX367723B MX367723B (es) 2019-09-03

Family

ID=52003015

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010446A MX387702B (es) 2013-10-25 2014-10-24 Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
MX2016005394A MX367723B (es) 2013-10-25 2014-10-24 Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010446A MX387702B (es) 2013-10-25 2014-10-24 Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.

Country Status (26)

Country Link
US (3) US9266883B2 (es)
EP (1) EP3060563B1 (es)
JP (3) JP6203954B2 (es)
KR (1) KR101862493B1 (es)
CN (1) CN105683188B (es)
AP (1) AP2016009156A0 (es)
AU (1) AU2014338549B2 (es)
BR (1) BR112016008276B1 (es)
CA (1) CA2927252C (es)
CL (1) CL2016000922A1 (es)
CR (1) CR20160191A (es)
DO (1) DOP2016000094A (es)
EA (1) EA028819B1 (es)
ES (1) ES2682493T3 (es)
IL (2) IL244819B (es)
MX (2) MX387702B (es)
NI (1) NI201600058A (es)
PE (1) PE20160546A1 (es)
PH (1) PH12016500756A1 (es)
PL (1) PL3060563T3 (es)
PT (1) PT3060563T (es)
SG (1) SG11201602183QA (es)
SV (1) SV2016005186A (es)
TN (1) TN2016000115A1 (es)
TR (1) TR201810944T4 (es)
WO (1) WO2015059668A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP6078640B2 (ja) * 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
CN104540809B (zh) * 2012-07-11 2018-12-11 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
AU2014338549B2 (en) * 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
AP2017009809A0 (en) 2014-10-03 2017-03-31 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives
WO2016054483A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016151501A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
KR20170114254A (ko) * 2016-03-24 2017-10-13 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10654836B2 (en) 2016-05-20 2020-05-19 Zhejiang Hisun Pharmaceutical Co., Ltd. Pyrimidine derivative, method for preparing same and use thereof in medicine
US11667631B2 (en) * 2016-05-20 2023-06-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. FGFR4 inhibitor, preparation method therefor, and applications thereof
KR20190038485A (ko) * 2016-05-27 2019-04-08 항저우 인노게이트 파마 컴퍼니 리미티드 Fgfr4 저해제인 헤테로 고리 화합물
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
TWI800489B (zh) * 2016-08-12 2023-05-01 大陸商江蘇豪森藥業集團有限公司 Ｆｇｆｒ４抑制劑及其製備方法和應用
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
US11229643B2 (en) 2016-11-02 2022-01-25 Novartis Ag Combinations of FGFR4 inhibitors and bile acid sequestrants
CN108264510A (zh) 2017-01-02 2018-07-10 上海喆邺生物科技有限公司 一种选择性抑制激酶化合物及其用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110997637B (zh) 2017-09-05 2022-09-27 保仕健生物科技(上海)有限公司 芳香类衍生物、其制备方法及其在医药上的应用
CN111164075A (zh) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 用作fgfr4抑制剂的稠环衍生物
CN110225913B (zh) * 2017-10-31 2021-10-15 江苏豪森药业集团有限公司 Fgfr4抑制剂晶型及其制备方法
CN110234649B (zh) * 2017-10-31 2021-10-15 江苏豪森药业集团有限公司 Fgfr4抑制剂的盐、晶体、制备方法及其用途
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物
CN109928968B (zh) * 2017-12-15 2021-11-05 成都华健未来科技有限公司 一类制备抗癌药物的中间体
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
CN111285871A (zh) * 2018-07-05 2020-06-16 成都华健未来科技有限公司 一种脲类化合物的新型晶型产品及制备方法
CN111285869A (zh) * 2018-07-05 2020-06-16 成都华健未来科技有限公司 脲类化合物的新型晶型产品及制备方法
TWI723480B (zh) 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3972920A1 (en) * 2019-05-21 2022-03-30 WestRock Packaging Systems, LLC Flexible pitch product metering system
CN114144176A (zh) * 2019-06-21 2022-03-04 拓臻制药公司 用于抑制fgfr4的化合物
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
CN113072550B (zh) * 2020-01-06 2023-08-08 周龙兴 一种高选择性成纤维细胞生长因子受体抑制剂和应用
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021355919A1 (en) 2020-10-05 2023-05-11 Chiome Bioscience Inc. Medicine for treating cancer
WO2022089648A1 (en) * 2020-11-02 2022-05-05 Jacobio Pharmaceuticals Co., Ltd. Crystalline forms of salts of fgfr4 inhibitor
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN115504965A (zh) 2021-06-23 2022-12-23 浙江海正药业股份有限公司 嘧啶类衍生物的晶型及其制备方法
WO2023082044A1 (zh) * 2021-11-09 2023-05-19 暨南大学 5-醛基杂环酰胺类化合物及其应用
CN116102549B (zh) * 2021-11-09 2025-02-11 暨南大学 5-醛基杂环酰胺类化合物及其应用
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025113607A1 (zh) * 2023-11-30 2025-06-05 石药集团中奇制药技术（石家庄）有限公司 联合治疗肿瘤的药物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6140338A (en) 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists
CN1284944A (zh) 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
WO1999041239A1 (en) 1998-02-10 1999-08-19 Novartis Ag B cell inhibitors
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
IL149313A0 (en) * 1999-11-08 2002-11-10 Merck & Co Inc Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
TW200305423A (en) 2002-02-14 2003-11-01 Ono Pharmaceutical Co N-carbamoyl nitrogen-containing condensed ring compound and medicament containing same as active ingredient
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7183413B2 (en) 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
KR101083506B1 (ko) 2005-07-15 2011-11-16 에프. 호프만-라 로슈 아게 신규한 헤테로아릴 융합된 환형 아민
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
WO2007079214A2 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
BRPI0808714A2 (pt) 2007-03-09 2014-08-12 Novartis Ag Uso de compostos, tais como 4-amino-5-fluoro-3-[6-(4-metil piperazinil-1)- 1h-benzimidazolil-2] quinolinona-(1h)-2 e tautômeros, sais, e misturas dos mesmos no preparo de medicamentos para o tratamento do melanoma
TWI577387B (zh) 2007-04-02 2017-04-11 建南德克公司 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ之用途
EP2234618A4 (en) 2007-12-21 2011-04-27 Scripps Research Inst BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102224170A (zh) 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
JPWO2010027002A1 (ja) 2008-09-05 2012-02-02 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
ES2462715T3 (es) 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
CN102725291B (zh) 2009-10-29 2016-12-21 西特里斯药业公司 作为沉默调节蛋白调节剂的双环吡啶和相关的类似物
KR20120101367A (ko) 2009-10-30 2012-09-13 노파르티스 아게 3-（2,6-디클로로-3,5-디메톡시-페닐）-1-｛6-［4-（4-에틸-피페라진-1-일）-페닐아미노］-피리미딘-4-일｝-1-메틸-우레아의 ｎ-옥시드
JPWO2011093501A1 (ja) 2010-02-01 2013-06-06 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
UA112061C2 (uk) 2010-07-29 2016-07-25 Райджел Фармасьютікалз, Інк. Активуючі ampk гетероциклічні сполуки і способи їх використання
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
PH12013501899A1 (en) 2011-03-18 2013-11-25 Lupin Ltd Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
WO2012138975A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN104540809B (zh) 2012-07-11 2018-12-11 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2922572A1 (en) 2012-11-23 2015-09-30 AB Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2015006492A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
PT3057943T (pt) 2013-10-18 2018-07-24 Eisai R&D Man Co Ltd Inibidores de fgfr4 pirimidina
AU2014338549B2 (en) * 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos

Also Published As

Publication number Publication date
US20150119385A1 (en) 2015-04-30
HK1222388A1 (en) 2017-06-30
JP6745856B2 (ja) 2020-08-26
PL3060563T3 (pl) 2018-10-31
PH12016500756A1 (en) 2016-05-30
US9533988B2 (en) 2017-01-03
BR112016008276B1 (pt) 2021-03-02
JP2019031553A (ja) 2019-02-28
US20170066766A1 (en) 2017-03-09
MX367723B (es) 2019-09-03
NI201600058A (es) 2016-06-21
ES2682493T3 (es) 2018-09-20
CL2016000922A1 (es) 2017-01-27
EP3060563B1 (en) 2018-05-02
IL263404A (en) 2018-12-31
CA2927252A1 (en) 2015-04-30
SG11201602183QA (en) 2016-05-30
KR101862493B1 (ko) 2018-05-29
MX2019010446A (es) 2019-10-17
IL263404B (en) 2019-09-26
JP2016534072A (ja) 2016-11-04
CN105683188A (zh) 2016-06-15
US9266883B2 (en) 2016-02-23
JP2017214411A (ja) 2017-12-07
EP3060563A1 (en) 2016-08-31
DOP2016000094A (es) 2016-07-15
AU2014338549A1 (en) 2016-04-14
EA028819B1 (ru) 2018-01-31
AU2014338549A8 (en) 2016-04-21
CA2927252C (en) 2021-09-28
AU2014338549B2 (en) 2017-05-25
KR20160075644A (ko) 2016-06-29
EA201690848A1 (ru) 2016-08-31
JP6429954B2 (ja) 2018-11-28
US9896449B2 (en) 2018-02-20
CR20160191A (es) 2016-07-01
MX387702B (es) 2025-03-18
US20160102092A1 (en) 2016-04-14
IL244819A0 (en) 2016-05-31
WO2015059668A1 (en) 2015-04-30
PE20160546A1 (es) 2016-05-26
PT3060563T (pt) 2018-07-26
IL244819B (en) 2018-12-31
SV2016005186A (es) 2016-11-21
JP6203954B2 (ja) 2017-09-27
CN105683188B (zh) 2018-02-09
TR201810944T4 (tr) 2018-08-27
AP2016009156A0 (en) 2016-04-30
TN2016000115A1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
SV2016005313A (es) Derivados de carboxamida
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
BR112016023991A2 (pt) ativadores de herg policíclicos
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35792A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos
CU20160170A7 (es) Derivados de carboxamida
CU20140127A7 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FG Grant or registration